Back to News
Market Impact: 0.3
Novartis Halts Development Of VHB937 After ASTRALS Phase 2 Trial Fails To Meet Endpoint
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Novartis said its ASTRALS Phase 2 trial of VHB937 for amyotrophic lateral sclerosis failed to meet both primary and secondary endpoints. The company will discontinue development of the investigational ALS therapy, eliminating the program from its pipeline and creating a negative read-through for the asset.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
NVS-0.85
More News
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Jensen Huang says Nvidia will sell twice as many chips next year
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go
- UK Lawmakers Say Thames Creditors Have Been Joyriding Family Car